Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...
Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, spoke with Managed Healthcare Executive, talks about the possible impacts ...
The funding agency aims to cap “indirect costs” in biomedical research grants. But this behind-the-scenes work is crucial to making research happen.
13h
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback